Loading
Life sciences · Journal article
BMC Pulmonary Medicine · September 12, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Mycobacterium chelonae is a rapidly growing nontuberculous mycobacterium that can cause severe infection in immunocompromised hosts. Cutaneous involvement may closely resemble metastatic disease, creating substantial diagnostic uncertainty, particularly in patients with advanced malignancy. A 68-year-old Asian man with stage IVB epidermal growth factor receptor-mutated lung adenocarcinoma, who was receiving systemic anticancer therapy and long-term dexamethasone, developed multiple progressive, painless subcutaneous nodules. Positron emission tomography–computed tomography demonstrated intense fluorodeoxyglucose uptake (maximum standardised uptake value 12.02), strongly suggesting cutaneous metastases. Initial skin biopsies were nondiagnostic. Approximately 4 months later, performance status (PS) worsened from 2 to 3; a repeat biopsy revealed tissue resembling pyogenic granuloma inflammation, and culture of purulent material from an open lesion grew M. chelonae, establishing a diagnosis of multifocal cutaneous nontuberculous mycobacterial infection. Targeted antimicrobial therapy with amikacin, azithromycin, and sitafloxacin resulted in marked improvement in the cutaneous lesions and PS from 3 to 2. Although further disease-directed treatment was limited, this improvement allowed the patient to resume S-1 chemotherapy in accordance with his treatment goals. Chemotherapy was continued briefly before disease progression required transition to best supportive care. Multifocal cutaneous M. chelonae infection should be considered in immunosuppressed patients with cancer presenting with new or progressive skin lesions, even when imaging findings strongly suggest metastatic disease. Early biopsy with mycobacterial culture and individualised treatment planning are essential for maintaining patient-centred care and quality of life.